Blueprint Medicines is a precision therapy company that invents medicines for people with cancer and blood disorders. Co. delivers its approved medicines, AYVAKIT®/AYVAKYT® (avapritinib) and GAVRETO® (pralsetinib), to patients in the U.S. and Europe, and it is globally developing multiple programs for systemic mastocytosis lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Co. is developing a portfolio of investigational EGFR inhibitors such as BLU-945, BLU-701, BLU-525 and BLU-451, to address a range of common and uncommon epidermal growth factor receptor activating mutations, including exon 19 deletions, the L858R mutation and exon 20 insertions. The BPMC YTD return is shown above.
The YTD Return on the BPMC YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether BPMC YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BPMC YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|